FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. SPGI
4. USO
5. ENOV
6. AON
7. AZN
8. AAPL
9. BLSM
10. GPRO

Go back to FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis

Insmed (INSM) PT Raised to $148 at Jefferies

August 12, 2025 2:49 PM EDT

Jefferies analyst Kelly Shi raised the price target on Insmed (NASDAQ: INSM) to $148.00 (from $129.00) while maintaining a Buy rating.

The analyst comments "INSM has been an attractive commercial biotech story in pulmonary space w/ repeated clinical success, winning an FDA approval today w/... More